Health TrialsbyHealthPanel

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

ConditionsGlaucoma, NeovascularVascular Endothelial Growth Factor Overexpression
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPrince of Songkla University

About this trial

To prospect studying the efficacy and safety of treating NVG with the intracameral versus the intravitreal injection of Bevacizumab.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of neovascular glaucoma

The patients having IOP > 21 mmHg, having the indication for trabeculectomy

The patients' age of at least 18-year-old

The patients having visual potential at least hand motion.

Disqualifiers

One eye patient

Patients having severe corneal edema or total hyphema obscure NVI or NVA view.

Cannot obtain endothelial cell count.

History of bevacizumab or fluorescence dye allergy.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intracameral injection

    Procedure/Surgery

    A/C injection of 1.25 mg/0.05 mL bevacizumab

  • Intravitreal injection

    Procedure/Surgery

    Vitreous injection of 1.25 mg/0.05 mL bevacizumab

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Intracameral injectionExperimental treatment 1 intervention
Group B: Intravitreal injectionExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

regression of nevolascularization

Amount of nevolascular of iris and angle regression

Time frame
2 months

Secondary outcomes

1

IOP reduction

IOP reduction at 2-month visit compare to baseline

Time frame
2 months
2

Injection complication

Hyphema, IOP spike

Time frame
2 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Prince of Songkla University

Lead sponsor

Source ClinicalTrials.gov
Apply now